(object) array( 'id' => '6877605', 'url' => 'FR/Angiotensin_II_Receptor_Blockers_(ARBs)', 'image' => '', 'title' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'tags' => array ( 0 => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'source_id' => 1038764, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084107', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Médicaments qui bloquent l\'action de l\'angiotensine II en l\'empêchant de se lier à des récepteurs de l\'angiotensine II sur les vaisseaux sanguins.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573051772930, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Angiotensin II Receptor Blockers (ARBs)', 'Definition' => 'Medications that block the action of angiotensin II by preventing angiotensin II from binding to angiotensin II receptors on blood vessels.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'CCTRADUCTION', 'Creation Date' => '2011/4/12', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Angiotensin_II_Receptor_Blockers_(ARBs)', )

(object) array( 'id' => '6228059', 'url' => 'FR/single_blind_masking', 'image' => '', 'title' => 'Etude en simple aveugle', 'tags' => array ( 0 => 'Etude en simple aveugle', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Etude en simple aveugle', 'source_id' => 4011054, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105915', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un type d\'étude en aveugle dans laquelle une partie impliquée dans l\'essai clinique, soit l\'investigateur soit le participant, ne sait pas à quels participants ont été assignées quelles interventions.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107970, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A type of masking in which one party involved with the clinical trial, either the investigator or participant, does not know which participants have been assigned which interventions.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'single blind masking', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'single_blind_masking', )

(object) array( 'id' => '7745839', 'url' => 'FR/investigational_treatment', 'image' => '', 'title' => 'Traitement expérimental', 'tags' => array ( 0 => 'Traitement expérimental', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Traitement expérimental', 'source_id' => 1259723, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084114', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le nouveau médicament ou thérapie testé dans l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821506, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'investigational treatment', 'Definition' => 'The new drug or therapy being tested in the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => 'experimental_treatment', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'investigational_treatment', )

(object) array( 'id' => '3898053', 'url' => 'FR/variable_interval_₁', 'image' => '', 'title' => 'Intervalle variable', 'tags' => array ( 0 => 'Intervalle variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle variable', 'source_id' => 3744244, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105901', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => '1) Un programme dans lequel une personne est renforcée par la première réponse après qu\'une période de temps variable soit passée depuis le renforcement précédent. Ce programme produit généralement un rythme de réponse uniforme. 2) Un programme de renforcement dans lequel une réponse est renforcée après qu\'une période de temps variable soit passée. Par exemple, dans un programme IV 30 secondes, l\'intervalle de temps varie entre chaque renforcement, mais l\'intervalle moyen de temps est de 30 secondes.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851728330752, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => '1) A schedule in which a person is reinforced for the first response after a varying period of time has passed since the previous reinforcement. This schedule usually causes a person to respond at a uniform rate. 2) A schedule of reinforcement in which one response is reinforced after a variable amount of time has passed. For example, on a VI 30-second schedule, the time to each reinforcement changes but the average time is 30 seconds.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'See Also' => 'interval schedules of reinforcement_₀', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable_interval_₁', )

(object) array( 'id' => '3897820', 'url' => 'FR/variable-interval_₁', 'image' => '', 'title' => 'Intervalle variable', 'tags' => array ( 0 => 'Intervalle variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle variable', 'source_id' => 3744241, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105901', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un renforçateur dépend de la première réponse après un intervalle de temps variable depuis la dernière opportunité pour un renforcement.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851727282176, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'A reinforcer is contingent on the first response after a variable interval of time since the last opportunity for reinforcement.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable-interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable-interval_₁', )

(object) array( 'id' => '6228625', 'url' => 'FR/publications_₂', 'image' => '', 'title' => 'Publications', 'tags' => array ( 0 => 'Publications', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Publications', 'source_id' => 4011325, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722110603', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Articles ou résumés scientifiques publiés concernant une étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507394292251885568, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'Published scientific articles or abstracts about a clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'publications', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'publications_₂', )

(object) array( 'id' => '6227764', 'url' => 'FR/sponsor_investigator', 'image' => '', 'title' => 'Sponsor-investigateur', 'tags' => array ( 0 => 'Sponsor-investigateur', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Sponsor-investigateur', 'source_id' => 4010894, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105912', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'La personne qui initie et conduit l\'étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107968, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The person who both initiates and conducts the clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'sponsor investigator', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'sponsor_investigator', )

(object) array( 'id' => '10479590', 'url' => 'FR/acne_vulgaris_₂', 'image' => '', 'title' => 'Acné vulgaire', 'tags' => array ( 0 => 'Acné vulgaire', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Acné vulgaire', 'source_id' => 5092397, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083415', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le type d\'acné le plus commun, caractérisé par des points noirs, des points blancs, des papules et des pustules, communément appelé boutons.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507928310838984705, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'The most common type of acne, associated with blackheads, whiteheads, papules, and pustules, commonly referred to as pimples or zits.', 'Part of Speech' => 'noun', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'MaryK', 'Creation Date' => '2013/3/15', 'Term' => 'acne vulgaris', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'acne_vulgaris_₂', )

(object) array( 'id' => '8442002', 'url' => 'FR/thiomersal', 'image' => 'Vaccines with thiomersal.jpg;', 'title' => 'Thiomersal', 'tags' => array ( 0 => 'Thiomersal', 1 => 'Pharmaceutical', 2 => 'Vaccines', 3 => '', ), 'term' => 'Thiomersal', 'source_id' => 274263, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Vaccines', ), 'lastedit' => '20150721084102', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le thimérosal est un conservateur contenant du mercure qui est souvent utilisé dans les vaccins en raison de ses propriétés antiseptiques et antifongiques. L\'utilisation du thimérosal comme conservateur de vaccin a été controversée au cours des dernières années en raison du risque potentiellement accru de provoquer l\'autisme chez les enfants. Cependant, la dernière étude du CDC a toutefois montré qu\'aucun lien n\'avait été trouvé entre le thimérosal et l\'autisme.', 'usage_comment' => '', 'glossary' => '', 'width' => 485, 'height' => 385, '_version_' => 1507294573052821508, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'thiomersal', 'Definition' => 'Thimerosal is a mercury-based preservative that is often used in vaccines because of its antiseptic and antifungal properties. The use of thimerosal as a vaccine preservative has been controversial in recent years due to potentially increased risk of causing children\'s autism. However, the latest CDC study however showed no link found between thimerosal and autism', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => '', 'Sample Image' => 'Vaccines with thiomersal.jpg;', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Vaccines', 'Domain' => 'Documentation; Marketing', 'Other Reference' => 'TIN', 'Creation User' => 'Williamb', 'Creation Date' => '2010/9/13', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'thiomersal', )

(object) array( 'id' => '2315639', 'url' => 'FR/spirulina_₁', 'image' => 'espirulina-3.jpg', 'title' => 'Spiruline', 'tags' => array ( 0 => 'Spiruline', 1 => 'Pharmaceutical', 2 => 'Healthcare supplement', 3 => '', ), 'term' => 'Spiruline', 'source_id' => 1658962, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Healthcare supplement', ), 'lastedit' => '20150721112809', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'La spiruline est une bactérie bleu-vert du groupe des cyanobactéries ayant une forte valeur nutritionnelle : elle contient des protéines et de la vitamine B12. Les compléments alimentaires sont composés de deux espèces de spiruline : Arthrospira platensis et Arthrospira maxima. Elle est devenue populaire en tant que complément alimentaire à la fin du XXe siècle.', 'usage_comment' => '', 'glossary' => '', 'width' => 250, 'height' => 280, '_version_' => 1507305079939530752, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'spirulina', 'Definition' => 'Spirulina is a green-blue bacterium of the Cyanobacteria group of a high nutritional value: it contains proteins and B12 vitamin. The nutritional supplements are made of two species of spirulina: Arthrospira platensis and Arthrospira maxima. It became popular as a nutritional supplement at the end of the XX century.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Healthcare supplement', 'Creation User' => 'esb', 'Creation Date' => '2011/10/6', 'Sample Image' => 'espirulina-3.jpg', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'spirulina_₁', )